ES2547480T3 - Lactobacillus acidophilus para su uso en reducir la incidencia y duración de infecciones respiratorias - Google Patents

Lactobacillus acidophilus para su uso en reducir la incidencia y duración de infecciones respiratorias Download PDF

Info

Publication number
ES2547480T3
ES2547480T3 ES07838266.0T ES07838266T ES2547480T3 ES 2547480 T3 ES2547480 T3 ES 2547480T3 ES 07838266 T ES07838266 T ES 07838266T ES 2547480 T3 ES2547480 T3 ES 2547480T3
Authority
ES
Spain
Prior art keywords
group
groups
children
days
probiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07838266.0T
Other languages
English (en)
Spanish (es)
Inventor
Gregory Leyer
Arthur Ouwehand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International N&H Denmark ApS
Original Assignee
DuPont Nutrition Biosciences ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2547480(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by DuPont Nutrition Biosciences ApS filed Critical DuPont Nutrition Biosciences ApS
Application granted granted Critical
Publication of ES2547480T3 publication Critical patent/ES2547480T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES07838266.0T 2006-10-02 2007-09-14 Lactobacillus acidophilus para su uso en reducir la incidencia y duración de infecciones respiratorias Active ES2547480T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84866206P 2006-10-02 2006-10-02
US848662P 2006-10-02
PCT/US2007/020033 WO2008042101A2 (en) 2006-10-02 2007-09-14 Probiotics for use in reducing the incidence and duration of illness

Publications (1)

Publication Number Publication Date
ES2547480T3 true ES2547480T3 (es) 2015-10-06

Family

ID=39268947

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07838266.0T Active ES2547480T3 (es) 2006-10-02 2007-09-14 Lactobacillus acidophilus para su uso en reducir la incidencia y duración de infecciones respiratorias
ES14186663T Active ES2650375T5 (en) 2006-10-02 2007-09-14 Probiotics for use in reducing symptoms of respiratory disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14186663T Active ES2650375T5 (en) 2006-10-02 2007-09-14 Probiotics for use in reducing symptoms of respiratory disease

Country Status (13)

Country Link
US (5) US20100040579A1 (enExample)
EP (2) EP2839836B2 (enExample)
JP (3) JP5896589B2 (enExample)
KR (2) KR101474188B1 (enExample)
CN (1) CN101528244B (enExample)
AU (1) AU2007302715B2 (enExample)
BR (1) BRPI0719787A2 (enExample)
DK (2) DK2839836T4 (enExample)
ES (2) ES2547480T3 (enExample)
FI (1) FI2839836T4 (enExample)
MX (1) MX2009003260A (enExample)
PL (2) PL2839836T5 (enExample)
WO (1) WO2008042101A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509151B1 (en) 2009-12-02 2014-08-20 KMW Inc. Device selection structure
JP5885287B2 (ja) * 2010-09-02 2016-03-15 アサヒカルピスウェルネス株式会社 インフルエンザの予防および／または治療剤
KR101806435B1 (ko) 2010-10-15 2017-12-07 시에이치알. 한센 에이/에스 면역보강제
EP2455092A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2455093A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
WO2015071389A1 (en) 2013-11-15 2015-05-21 Nestec S.A. Compositions for use in the prevention or treatment of urt infections in infants or young children at risk
CN103798392B (zh) * 2014-03-07 2015-12-30 内蒙古伊利实业集团股份有限公司 具有缓解咽喉部炎症功效的益生菌食品组合物及食品
AU2016227595B2 (en) 2015-03-05 2020-08-27 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
WO2020170982A1 (ja) 2019-02-21 2020-08-27 オリンパス株式会社 フローラ治療用留置体、フローラ治療法
WO2021062250A1 (en) 2019-09-25 2021-04-01 Tall Goods, Llc Methods for producing probiotics fortified avian eggs and egg products and formulations thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007A (en) * 1845-04-22 Improvement in separating tannin and coloring-matter in quercitron-bark
AU5113798A (en) * 1996-11-29 1998-06-22 Bio K & International Inc. Lactic ferment comprising a particular strain of (lactobacillus acidophilus) and use thereof
JP4212838B2 (ja) * 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
MXPA05003597A (es) 2002-10-11 2005-06-03 Wyeth Corp Formulaciones nutricionales que contienen sustancias simbioticas.
RU2407784C2 (ru) * 2003-12-17 2010-12-27 Н.В. Нютрисиа Пробиотический штамм lactobacillus casei, продуцирующий молочную кислоту, применение штамма для приготовления питательной композиции для лечения или профилактики легочной дисфункции, питательная композиция и способ ее получения, лекарственное средство для лечения или профилактики хронической обструктивной болезни легких у субъекта и применение штамма для приготовления лекарственного средства, контейнер
DE102004026706A1 (de) * 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
CA2470090A1 (fr) * 2004-06-18 2005-12-18 Bio-K Plus International Inc. Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20042189A1 (it) * 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
US7981412B2 (en) * 2005-02-15 2011-07-19 Gorbach Sherwood L Food containing a probiotic and an isolated β-glucan and methods of use thereof
US20070020249A1 (en) * 2005-04-29 2007-01-25 Downs Bernard W Compositions for prevention and treatement of symptoms of gastrointestinal distress
EP1951273B1 (en) 2005-10-06 2014-02-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases

Also Published As

Publication number Publication date
US20140356329A1 (en) 2014-12-04
EP2839836B1 (en) 2017-08-30
EP2839836B2 (en) 2024-06-26
MX2009003260A (es) 2009-05-11
CN101528244B (zh) 2012-01-11
CN101528244A (zh) 2009-09-09
KR20140002069A (ko) 2014-01-07
ES2650375T3 (es) 2018-01-18
US20200316145A1 (en) 2020-10-08
JP5896589B2 (ja) 2016-03-30
BRPI0719787A2 (pt) 2014-11-25
US20180000875A1 (en) 2018-01-04
JP2014058558A (ja) 2014-04-03
KR20090063222A (ko) 2009-06-17
PL2839836T5 (pl) 2025-11-17
PL2068899T3 (pl) 2015-12-31
KR101474188B1 (ko) 2014-12-17
EP2068899A2 (en) 2009-06-17
DK2839836T3 (en) 2017-12-04
KR101485200B1 (ko) 2015-01-26
EP2839836A1 (en) 2015-02-25
US20100040579A1 (en) 2010-02-18
JP2016128478A (ja) 2016-07-14
WO2008042101A2 (en) 2008-04-10
AU2007302715A1 (en) 2008-04-10
JP2010505824A (ja) 2010-02-25
WO2008042101A3 (en) 2009-04-09
EP2068899B1 (en) 2015-07-01
AU2007302715B2 (en) 2013-01-31
FI2839836T4 (fi) 2024-08-26
DK2839836T4 (da) 2024-08-26
PL2839836T3 (pl) 2018-02-28
US20230256037A1 (en) 2023-08-17
DK2068899T3 (da) 2015-09-28
ES2650375T5 (en) 2025-02-03

Similar Documents

Publication Publication Date Title
ES2547480T3 (es) Lactobacillus acidophilus para su uso en reducir la incidencia y duración de infecciones respiratorias
Tojo et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis
Maldonado et al. Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants
Hojsak et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial
Lenoir-Wijnkoop et al. Probiotic and prebiotic influence beyond the intestinal tract
Quigley Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults
Esposito et al. Do children’s upper respiratory tract infections benefit from probiotics?
Balakrishnan et al. Prebiotics, probiotics and digestive health
ES2399775T3 (es) Composiciones farmacéuticas que comprenden L. acidophilus y bifidobacterium lactis para el uso en el tratamiento de un trastorno intestinal funcional
Zhao et al. Investigating dysbiosis and microbial treatment strategies in inflammatory bowel disease based on two modified Koch’s postulates
Ripoll et al. scFOS supplemented follow-on formula in healthy infants: Impact on vaccine specific faecal secretory IGA response, faecal bifidobacteria, growth and digestive tolerance
Mosaddek et al. Effect of probiotics in the treatment of acute watery diarrhoea in children admitted to a tertiary care hospital in Bangladesh: a non-randomized prospective clinical trial
Banerjee et al. Importance of probiotics in human health
Quigley Probiotics in gastrointestinal disorders
RU2322251C2 (ru) Способ комплексной коррекции дисбиоза кишечника с помощью жидкого пробиотика "нарине-форте" и пребиотика сиропа "фитолон" с хлорофиллом
AU2013201783B2 (en) Probiotics for use in reducing the incidence and duration of illness
Cho et al. Report on'Bifidus' yogurt products in the Korean domestic market reflecting its regulated counting of bifidobacteria according to revised food code 2015
Floch Probiotics
Allen et al. Cochrane Review: Probiotics for treating acute infectious diarrhoea
Gazal Abu Syed Md. Mosaddek, M. Rinat Rizvi c#, Rumi Akter d, Md. Saiful Islam e, Md. Nurul Hossain f, Hrishik Iqbal g
Lee et al. HUMAN INTESTINAL MICROBIOTA AND HEALTHY AGING
Avadhani Probiotics: Review of evidenc
Whittaker Probiotics: medicine cupboard